GP49A Inhibitors
GP49A inhibitors encompass a broad range of chemicals primarily targeting kinases and signaling pathways that play roles in immunological responses. These inhibitors can act upon various key signaling molecules like PI3 kinase, Src kinases, MEK, and members of the MAPK family, such as JNK and p38. Inhibition of these molecules can result in downstream disruption of cellular signaling cascades where GP49A may operate.
Additionally, inhibitors that target transcription factors and their activators, such as NF-κB and STAT3, are crucial given the relevance of these factors in immune and inflammatory processes. The JAK-STAT pathway, specifically inhibited by molecules like Ruxolitinib, is another central cascade in immune responses. These chemical inhibitors, while not directly targeting GP49A, are significant due to their capacity to alter the cellular environment and, by extension, the signaling events GP49A is involved in.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3 kinase inhibitor. As PI3 kinase is involved in various cell signaling pathways, inhibiting this enzyme can modulate GP49A-associated pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Another PI3 kinase inhibitor that can disrupt signaling cascades that GP49A may be involved in. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Src family kinase inhibitor. Since Src kinases play roles in immunoreceptor signaling, inhibiting them can impact GP49A's potential signaling events. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A broad-spectrum tyrosine kinase inhibitor that can block many signaling pathways, possibly including those associated with GP49A. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
This MEK inhibitor can impact MAPK signaling and, by extension, affect the pathways where GP49A operates. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor. By blocking JNK, a component of the MAPK pathway, it can indirectly modulate GP49A-associated signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
P38 MAPK inhibitor. As p38 is another arm of the MAPK pathway, inhibiting it can indirectly influence GP49A's role. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
NF-κB pathway inhibitor. Given the role of NF-κB in inflammation and immune responses, its inhibition can influence GP49A-associated reactions. | ||||||
Stat3 inhibitor V, stattic | 19983-44-9 | sc-202818 sc-202818A sc-202818B sc-202818C sc-202818D sc-202818E sc-202818F | 25 mg 100 mg 250 mg 500 mg 1 g 2.5 g 5 g | $130.00 $196.00 $274.00 $512.00 $731.00 $1408.00 $2091.00 | 114 | |
Specifically inhibits the activation of STAT3, a transcription factor involved in various immune processes. This can indirectly affect GP49A's signaling pathways. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK1/2 inhibitor. By targeting the JAK-STAT pathway, which is pivotal for various immune responses, it can potentially influence processes where GP49A is implicated | ||||||